Author information:
(1)Randall Children's Hospital at Legacy Emanuel, Children's Cancer and Blood 
Disorders Program, Portland, OR 97227, USA.
(2)Division of Pediatric Hematology Oncology, Oregon Health and Science 
University, Portland, OR 97239, USA.
(3)Division of Oncology, Center for Applied Medical Research (CIMA), University 
of Navarra, 31008 Pamplona, Spain.
(4)Division of Hematology and Medical Oncology, Oregon Health and Science 
University, Portland, OR 97239, USA.
(5)Knight Cancer Institute, Oregon Health and Science University, Portland, OR 
97239, USA.
(6)Department of Molecular and Medical Genetics, Oregon Health and Science 
University, Portland, OR 97239, USA.
(7)Research and Development, Oncotide Pharmaceuticals, Research Triangle Park, 
NC 27710, USA .
(8)Spyryx Biosciences, Durham, NC 27713, USA.
(9)Division of Bioinformatics and Computational Biology, Department of Medical 
Informatics and Clinical Epidemiology, Oregon Health and Science University, 
Portland, OR 97239, USA.
(10)Dana-Farber Cancer Institute, Harvard Cancer Center, Boston, MA 02215, USA.
(11)Department of Cell and Developmental Biology, Oregon Health and Science 
University, Portland, OR 97239, USA.
(12)Research and Development, Oncotide Pharmaceuticals, Research Triangle Park, 
NC 27710, USA.
(13)Department of Molecular and Medical Genetics, Oregon Health and Science 
University, Portland, OR USA-97239.
(14)Knight Cancer Institute, Oregon Health and Science University, Portland, OR, 
USA-97239.
(15)Division of Hematology and Medical Oncology, Oregon Health and Science 
University, Portland, OR, USA-97239.